Abstract 1733P
Background
Madrid has been the epicenter of the SARS-CoV2 pandemic in Spain. We analyzed the experience at our hospital with SARS-CoV2 infection and cancer patients (p).
Methods
We analyzed our experience from March 1 to April 30 at the Puerta de Hierro University Hospital in Madrid. Diagnosis of SARS-CoV2 infection was made by RT-PCR, suspected cases not confirmed were excluded.
Results
Overall in-hospital mortality cancer p with COVID-19 was 15.2% (95%CI, 6.3; 5.2), similar to 12.7% (95%CI,11.1;4.4) with p=0.615 of the global COVID-19 hospitalised population and greater than that of patients admitted without SARS-CoV-2 infection during the same period 4.3% (95%CI; 3.6;5.2) p<0.001. Among 653 patients receiving active cancer therapy during this period, 24 (3.7%) developed COVID-19 and required admission, 4.2% of were receiving chemotherapy, 9.5% immunotherapy and 2.1% targeted therapies. Lung and breast cancer were the most frequent (26.1%), followed by colorectal (19.6%) and breast cancer. No significant differences due to the cancer treatment received were observed. Mortality in lung cancer patients was the highest (25%). The univariate analysis (between p who developed serious event vs. those who did not), showed that higher Brescia, CURB-65 scale, lactate dehydrogenase (LDH) or C-reactive protein (CRP) levels at admission, the greater risk of developing severe complications (p<0.05) Table: 1733P
| VARIABLE | OTHER CANCER N=34 (%) | LUNG CANCER N=12 (%) | |
| Male | 52.9 | 50 | |
| Age mean | 63.9 | 63.5 | |
| Active Smoking | 0 | 16.7 | |
| Ex-smokers | 35.3 | 50 | |
| COMORBIDITIES | |||
| Coronary heart disease | 8.8 | 16.7 | |
| Hypertension | 35.3 | 41.7 | |
| COPD | 8.8 | 16.7 | |
| Dyslipidemia | 23.5 | 25 | |
| STAGE | |||
| IV | 52.9 | 50 | |
| SYMPTOMS | p | ||
| Neutropenia | 6.1 | 0 | 1.0 |
| Cough | 67.6 | 41.7 | .17 |
| Temperature | 37.1 | 37.3 | .36 |
| Dyspnoea | 47 | 91.7 | .007 |
| Diarrhea | 8.8 | 8.3 | 1.0 |
| Lymphopenia | 68.7 | 36.4 | .08 |
| PROGNOSTIC CRITERIA | |||
| IL6 | .41 | ||
| D-DIMER | 0.9 (0.6; 2.2) | 0.9 (0.5; 2.7) | .57 |
| PCR | 107.7 | .44 | |
| LDH | 266 (207; 326) | 290 (238; 352) | .19 |
| FERRITIN | 562 (358; 933) | 1111 (392; 2672) | .15 |
| CHARLSON INDEX* | 8 (6; 9) | 8 (6; 9) | .80 |
| CURB65 SCALE ** | .31 | ||
| BRESCIA SCALE | .17 |
Conclusions
Patients with cancer, especially lung cancer, and SARS-CoV2 infection have a worse overall prognosis than the general population. Objective parameters such as LDH, CRP at admission, Brescia index or CURB-65 should alert us to a more serious evolution and suggest early an early intensive care unit (ICU) admission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.